Author Affiliations: Departments of Dermatology (Drs Sempau, Gonz ález-Sixto, S ánchez-Sambucetty, P érez-Bustillo, and Rodr íguez-Prieto) and Immunology (Dr Ruiz de Morales), Complejo Asistencial Universitario de Le ón, Le ón, Spain.
The use of drugs that block the action of tumor necrosis factor α increases the risk of reactivation of latent tuberculosis infection (LTI).1 Screening before beginning treatment reduces the number of cases of tuberculosis by up to 78% to 85%.2
We describe 3 patients who were treated with anti –tumor necrosis factor α and in whom a combined tuberculin test (TT) and interferon gamma release assay (IGRA) (QuantiFERON-TB Gold; Cellestis Inc, Valencia, California) allowed the diagnosis of a recent contact or an LTI that would have not been detected with a TT alone (Table).
Sempau L, Gonz ález-Sixto B, S ánchez-Sambucetty P, Ruiz de Morales JMGÍ, P érez-Bustillo A, Rodr íguez-Prieto MA. Double Screening for Latent Tuberculosis Infection in Patients Treated With Anti –Tumor Necrosis Factor α. Arch Dermatol. 2011;147(10):1233–1234. doi:10.1001/archdermatol.2011.270
Coronavirus Resource Center
Customize your JAMA Network experience by selecting one or more topics from the list below.
Create a personal account or sign in to: